港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,787.578

-5.464-0.30%

漲家數：2

跌家數：4

平家數：2

市盈率：- -

高：1,840.451

開：1,793.941

低：1,762.516

收：1,793.042

資料載入中...

通化東寶(600867.SH)：GLP-1/GIP雙靶點受體激動劑獲得降糖適應症Ib期臨牀試驗總結報告

賽諾菲(SNY.US)與梯瓦(TEVA.US)共同開發的duvakitug預計在下半年啓動3期臨牀試驗

PCHi 2025觀察：珠光顏料成彩妝“風向標”，多肽為個護品類“掌中寶”

港股異動 | 康方生物(09926)漲超5% 依沃西將與輝瑞多個ADCs藥物開展聯合療法臨牀試驗

昭衍新藥盤中異動臨近午盤大幅拉昇5.11%報13.980港元

【AH互動】康希諾生物漲近11% A股升逾5% DTcPHib-MCV4聯合疫苗獲批開展臨牀試驗

方達控股盤中異動股價大漲5.69%報1.300港元

康希諾生物持續上漲逾12% DTcP-Hib-MCV4聯合疫苗獲得藥物臨牀試驗批准

藥明康德(02359)出現大手成交15.3萬股，成交價$60.925，涉資932.152萬

阿斯达克财经

招銀國際：內地藥品價格政策有望優化醫療AI加速商業化落地

華東醫藥：GLP-1/GIP雙靶點長效激動劑HDM1005注射液新適應症中國IND獲得批准

維亞生物盤中異動股價大跌5.56%報1.360港元

康龍化成盤中異動股價大跌5.19%

康方生物(09926.HK)依沃西與輝瑞(PFE.US)ADCs藥物開展聯合療法臨牀試驗

阿斯达克财经

迪安診斷：本次交易已完成全部法定程序及交割手續

“藥明系”股價跌超9% 公司：不對資本市場波動及其原因進行評論

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=12"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1787.5779,"timestamp":1741594084354,"preClose":1793.0419,"halted":0,"volume":80771814,"delay":0,"changeRate":-0.003047,"change":-5.463989,"pbRate":2.65369,"amount":1784097230,"amplitude":0.043465,"prevYearClose":1395.7731,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"turnoverRate":0.006914,"marketCap":379404801152,"floatMarketCap":166674436992,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1840.4508,"amplitude":0.043465,"preClose":1793.0419,"low":1762.5157,"pbRate":"2.65369","latestPrice":1787.5779,"volume":80771814,"delay":0,"open":1793.9412,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"sixtyDayClose":1409.843,"secType":"PLATE","market":"HK","turnoverRate":0.006914,"peRate":33.079805,"marketCap":379404801152,"floatMarketCap":166674436992,"timestamp":1741594084354,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":4,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:12,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514549320","title":"通化東寶(600867.SH)：GLP-1/GIP雙靶點受體激動劑獲得降糖適應症Ib期臨牀試驗總結報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2514549320","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514549320?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 16:09","pubTimestamp":1740470979,"startTime":"0","endTime":"0","summary":"格隆汇2月25日丨通化东宝公布，全资子公司东宝紫星（杭州）生物医药有限公司完成了一项关键Ib期临床试验并获得临床试验总结报告，研究结果显示达到主要终点目标。公司在获得注射用THDBH120药物临床试验批准后，根据国内化学药品创新药相关指导原则，近日完成了一项“在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床研究”，研究结果达到了主要终点目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25160948369004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","03347","600867","BK0188","BK4144","BK1141","GLP","BK0196","BK1576","BK4590","BK1583"],"gpt_icon":0},{"id":"2514803042","title":"賽諾菲(SNY.US)與梯瓦(TEVA.US)共同開發的duvakitug預計在下半年啓動3期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803042?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 14:33","pubTimestamp":1740465193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲与梯瓦日前公布了其共同开发的在研单抗duvakitug在2b期临床试验RELIEVE UCCD中获得的详细结果。新闻稿表示，这一结果展现了duvakitug成为“best-in-class”疗法的潜力。两家公司预计在今年下半年启动3期临床试验。2b期临床试验数据显示，接受duvakitug治疗的UC患者中，36%的低剂量组和48%高剂量组患者实现临床缓解，此数值在安慰剂组仅为20%。靶向TL1A有望缓解IBD患者的过度免疫反应。赛诺菲与梯瓦在2023年达成合作，共同开发并商业化duvakitug，用于治疗UC和CD。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK4596","BK1576","BK4584","BK4559","BK1141","BK1583","BK4557","BK4585","BK4588","IE00BFXG1179.USD","BK4007","BK4566","TEVA","SNY"],"gpt_icon":0},{"id":"2514667058","title":"PCHi 2025觀察：珠光顏料成彩妝“風向標”，多肽為個護品類“掌中寶”","url":"https://stock-news.laohu8.com/highlight/detail?id=2514667058","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514667058?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 14:16","pubTimestamp":1740464218,"startTime":"0","endTime":"0","summary":"第15届中国国际化妆品个人及家庭护理用品原料展览会于2月19-21日在广州举办。根据展会信息，PCHi 2025汇聚全球20多个国家，800家化妆品原料、检测、设备相关企业参展，展览面积超过6万平方米。PCHi展会历来是业内人士的必争之地，而PCHi 2025更是为参展企业提供了一个展示自身实力、提升品牌形象的绝佳舞台。由于衰老是所有化妆品消费者所面临的共同“难题”，因此对延缓个体或生物体衰老过程，成为护肤行业经久不衰，热度最高的主题。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/OWQ4NGY3MGJmOTZjMTUwZjdhOTdjYjQwNjE1MDM0NDE4NQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OWQ4NGY3MGJmOTZjMTUwZjdhOTdjYjQwNjE1MDM0NDE4NQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1953846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2045819591.USD","06616","BK1207","BK1587","LU1046422090.SGD","LU2125910500.SGD","LU2488822045.USD","LU0052750758.USD","02145","02359","06821","01318","BK1576","BK1141","BK1583","LU0708995583.HKD","BK1191","LU2242644610.SGD","02367","LU0320764599.SGD","BK1129"],"gpt_icon":0},{"id":"2514034005","title":"港股異動 | 康方生物(09926)漲超5% 依沃西將與輝瑞多個ADCs藥物開展聯合療法臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514034005","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514034005?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 13:41","pubTimestamp":1740462061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超5%，截至发稿，涨4.81%，报71.95港元，成交额9.44亿港元。消息面上，2月24日，康方生物宣布，依沃西国际市场开发合作伙伴Summit Therapeutics已与辉瑞达成临床试验合作，共同推进康方生物自主研发的PD-1/VEGF双抗依沃西与辉瑞多款抗体偶联药物在多种实体瘤中的联合治疗应用。公司指，此次合作的目标是深入挖掘依沃西联合辉瑞多款vedotin系列ADCs药物联合疗法在多种实体瘤中的协调潜力，加速推进可能重塑治疗格局的创新联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE000M9KFDE8.USD","BK1576","IE00B543WZ88.USD","BK4588","IE00BPRC5H50.USD","SG9999011175.SGD","SG9999003800.SGD","LU1066051498.USD","LU0348784397.USD","SG9999001176.SGD","BK4568","BK4581","LU0170899867.USD","LU0456855351.SGD","LU1894683264.USD","LU0306806265.USD","PFE","SG9999002232.USD","BK4592","SG9999001176.USD","LU0289739699.SGD","03347","BK1574","LU0234572021.USD","09926","SGXZ57979304.SGD","LU0122379950.USD","LU1794554557.SGD","BK4007","SG9999013999.USD","LU0321505439.SGD","LU0868494617.USD","LU0225771236.USD","LU0225284248.USD","LU0348783233.USD","SG9999002224.SGD","IE00BLSP4452.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU1023059063.AUD","LU1894683348.USD","LU0058720904.USD","IE00B19Z3581.USD","BK1141","LU2488822045.USD","LU1720050803.USD","BK4585","BK4550","LU0985481810.HKD"],"gpt_icon":0},{"id":"2514035722","title":"昭衍新藥盤中異動 臨近午盤大幅拉昇5.11%報13.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514035722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514035722?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 11:53","pubTimestamp":1740455597,"startTime":"0","endTime":"0","summary":"2025年02月25日临近午盘11时53分，昭衍新药股票出现异动，股价急速拉升5.11%。截至发稿，该股报13.980港元/股，成交量251.577万股，换手率2.11%，振幅10.38%。资金方面，该股资金流入1375.07万港元，流出1499.68万港元。昭衍新药股票所在的生物技术行业中，整体涨幅为1.35%。其相关个股中，创胜集团-B、康希诺生物、基石药业-B涨幅较大，振幅较大的相关个股有药明巨诺-B、康希诺生物、腾盛博药-B，振幅分别为18.40%、17.64%、16.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225115317a252c989&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225115317a252c989&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","06127"],"gpt_icon":0},{"id":"2514038757","title":"【AH互動】康希諾生物漲近11% A股升逾5% DTcPHib-MCV4聯合疫苗獲批開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038757","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038757?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 11:15","pubTimestamp":1740453354,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康希诺生物 早盘股价强势走高，暂报38港元，涨幅10.79%，成交额1.24亿港元。消息面上，公司近日公告称，公司研发的吸附无细胞百(组分)白破b型流感嗜血杆菌(结合)-ACYW135群脑膜炎球菌(结合)联合疫苗已获得中国国家药品监督管理局批准，可以开展相关临床试验。对此，公司回应称，结合肺炎疫苗市场情况，公司已布局更高价的肺炎结合疫苗，以增强肺炎产品组合的竞争力，尚处于临床前的开发阶段，未来如有阶段性进展，将及时分享。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111617962f498e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111617962f498e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1576","BK1141","06185","BK1574","BK1191","BK1583","BK1515","03347"],"gpt_icon":0},{"id":"2514038784","title":"方達控股盤中異動 股價大漲5.69%報1.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038784","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038784?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 11:11","pubTimestamp":1740453066,"startTime":"0","endTime":"0","summary":"2025年02月25日早盘11时11分，方达控股股票出现异动，股价急速拉升5.69%。截至发稿，该股报1.300港元/股，成交量201万股，换手率0.10%，振幅8.13%。资金方面，该股资金流入190.026万港元，流出43.802万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。方达控股股票所在的生物技术行业中，整体涨幅为0.75%。该公司的部门包括北美和欧洲以及中国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111106abdbb89f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111106abdbb89f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01521","BK1576","BK1141"],"gpt_icon":0},{"id":"2514038954","title":"康希諾生物持續上漲逾12% DTcP-Hib-MCV4聯合疫苗獲得藥物臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038954","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038954?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 11:05","pubTimestamp":1740452700,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　康希诺生物（06185）早盘持续走高，股价上涨12.54%，现报38.60港元，成交额1.14亿港元。\n　　康希诺生物公布，公司研发的吸附无细胞百（组分）白破（“DTcP”）b型流感嗜血杆菌（结合）（“Hib”）-ACYW135群脑膜炎球菌（结合）（“MCV4”）联合疫苗（“DTcPHib-MCV4联合疫苗”）已获得中国国家药品监督管理局批准，可以开展相关临床试验。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-25/doc-inemsfym1428950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1191","03347","BK1515","06185","BK1583","BK1576","BK1141"],"gpt_icon":0},{"id":"2514087174","title":"藥明康德(02359)出現大手成交15.3萬股，成交價$60.925，涉資932.152萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2514087174","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514087174?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 10:20","pubTimestamp":1740450000,"startTime":"0","endTime":"0","summary":"[大手成交]药明康德(02359)在上午10:20出现大手成交，成交量为15.3万，成交价为港币$60.925，涉资932.152万。至目前为止，股价跌3.18%，今日最高价为$61.5，而最低价为$60.1，总成交量为517.695万股，总成交金额港币$3.149亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2502255657/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1046422090.SGD","LU2242644610.SGD","BK1141","LU0052750758.USD","02359","BK1583","LU1997245094.SGD","LU2488822045.USD","603259","BK1576","LU0320764599.SGD","BK0216","LU0456842615.SGD","LU1997245177.USD","LU2045819591.USD","LU2125910500.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2514129084","title":"招銀國際：內地藥品價格政策有望優化 醫療AI加速商業化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2514129084","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514129084?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 09:50","pubTimestamp":1740448233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，维持内地医药行业“优于大市评级”。MSCI中国医疗指数2025年初至今累计上涨11.5%，跑输MSCI中国指数1.2%。受益于国内药品价格政策优化、国内宏观环境改善以及海外降息预期，医药行业有望在2025年继续迎来估值修复。报告指，丙类医保目录年内即将落地，创新药将覆盖获得更好的支付环境；医疗设备招标加速复苏，将推动国产医疗设备企业盈利复苏。该行看好行业估值修复，推荐买入信达生物(01801)、百济神州(06160)、三生制药(01530)、联影医疗(688271.SH)、巨子生物(02367)、药明康德(02359)、科伦博泰生物-B(06990)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","BK1576","LU0588546209.SGD","02359","BK1141","LU2488822045.USD","LU1046422090.SGD","BK1593","01801","LU2125910500.SGD","LU0320764599.SGD","BK1161","01530","BK1500","BK1589","LU0708995583.HKD","150261","LU2242644610.SGD","BK1583","BK1588","LU2045819591.USD","02367","LU0052750758.USD","LU0307460666.USD","BK1207","06160","LU1969619763.USD"],"gpt_icon":0},{"id":"2514813230","title":"華東醫藥：GLP-1/GIP雙靶點長效激動劑HDM1005注射液新適應症中國IND獲得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514813230","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514813230?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 09:37","pubTimestamp":1740447447,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0187","BK0209","BK0183","GLP","LU2328871848.SGD","LU1969619763.USD","BK1191","BK1576","000963","BK4590","BK0175","BK1583","BK1141","BK4144","BK0188","BK0196","03347","BK1574","01477","BK0132"],"gpt_icon":0},{"id":"2514819410","title":"維亞生物盤中異動 股價大跌5.56%報1.360港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819410","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819410?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 09:34","pubTimestamp":1740447248,"startTime":"0","endTime":"0","summary":"2025年02月25日早盘09时34分，维亚生物股票出现波动，股价大幅跳水5.56%。截至发稿，该股报1.360港元/股，成交量54.1万股，换手率0.03%，振幅2.78%。资金方面，该股资金流入39.9545万港元，流出12.3215万港元。维亚生物股票所在的生物技术行业中，整体跌幅为1.82%。其相关个股中，华康生物医学、正大企业国际、科笛-B涨幅较大，振幅较大的相关个股有药明巨诺-B、科笛-B、腾盛博药-B，振幅分别为9.91%、7.98%、6.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225093408a252a312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225093408a252a312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","01873","BK1576"],"gpt_icon":0},{"id":"2514081191","title":"康龍化成盤中異動 股價大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514081191","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514081191?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 09:30","pubTimestamp":1740447020,"startTime":"0","endTime":"0","summary":"2025年02月25日早盘09时30分，康龙化成股票出现波动，股价快速下挫5.19%。截至发稿，该股报16.820港元/股，成交量27.96万股，换手率0.10%，振幅1.80%。康龙化成股票所在的药品行业中，整体跌幅为0.28%。其相关个股中，联康生物科技集团、长江生命科技、海王英特龙涨幅较大，振幅较大的相关个股有开拓药业-B、信达生物、康龙化成，振幅分别为2.68%、2.47%、1.80%。扣除这部分收益后，2024年康龙化成的扣非净利润则预计同比下降24%～29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502250930209891816f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502250930209891816f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","03759"],"gpt_icon":0},{"id":"2514862360","title":"康方生物(09926.HK)依沃西與輝瑞(PFE.US)ADCs藥物開展聯合療法臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862360","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514862360?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 08:55","pubTimestamp":1740444900,"startTime":"0","endTime":"0","summary":"康方生物公布，公司自主研发的全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物依沃西单抗注射液，其国际市场开发合作伙伴Summit Therapeutics已与美国辉瑞达成临床试验合作，将共同推进依沃西与辉瑞多款抗体偶联药物在多种实体瘤中的联合治疗应用。目前依沃西在全球开展临床试验药物均由康方生物生产供应。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200914151047405_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200914151047405_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419847/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0348784397.USD","LU1794554557.SGD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348783233.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","BK1141","BK1161","BK1576","BK1574","03347","09926","LU1720050803.USD","BK1583"],"gpt_icon":0},{"id":"2514089535","title":"迪安診斷：本次交易已完成全部法定程序及交割手續","url":"https://stock-news.laohu8.com/highlight/detail?id=2514089535","media":"互动易","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514089535?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 08:54","pubTimestamp":1740444840,"startTime":"0","endTime":"0","summary":"有投资者向迪安诊断提问， 问下董秘，2024年9.27你公司公布，要向泰格医药协议转让 观合医药 公司，问下目前什么进展了？是否收到款项？企查查显示股份还未变，是不是这次转让失败了，麻烦回复下！公司回答表示，尊敬的投资者，您好！本次交易已完成全部法定程序及交割手续。根据《中华人民共和国市场主体登记管理条例》相关规定，观合医药作为股份制企业，仅需就发起人变更履行备案登记义务，第三方平台信息存在滞后性。谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225090520a2529a1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225090520a2529a1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1576","BK1583","BK1141"],"gpt_icon":0},{"id":"2514224773","title":"“藥明系”股價跌超9% 公司：不對資本市場波動及其原因進行評論","url":"https://stock-news.laohu8.com/highlight/detail?id=2514224773","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514224773?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 23:59","pubTimestamp":1740412743,"startTime":"0","endTime":"0","summary":"消息面上，特朗普签署投资政策备忘录，宣布将调整美国投资政策，重点进一步限制与中国的双向投资，医疗等被列为限制领域。此前，“药明系”股价就多次因美国生物法案的相关信息而产生波动。药明生物今年1月宣布出售爱尔兰疫苗设施资产针对2月24日的股价波动，药明生物方面回复《每日经济新闻》记者称，公司不对资本市场波动及其原因进行评论。这一交易被市场视为药明生物应对潜在的国际市场风险的防御性举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235953962ead40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235953962ead40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU0348825331.USD","LU0979878070.USD","02269","LU0819121731.USD","LU1794554557.SGD","LU1242518857.USD","BK1589","LU0588546209.SGD","LU0417516738.SGD","LU0456846285.SGD","LU0417516902.SGD","LU0326950275.SGD","SG9999002463.SGD","LU0320764599.SGD","LU0327786744.USD","LU0823426308.USD","BK1521","BK1576","LU1720050803.USD","LU1880383366.USD","LU1688375341.USD","LU0516423091.SGD","LU0516423174.USD","IE00B0JY6N72.USD","BK1141","LU0039217434.USD","LU0359201612.USD","LU0823426480.USD","LU0052750758.USD","LU1242518931.SGD","LU0572944931.SGD","LU0516422440.USD","LU0516422952.EUR","LU0516422366.SGD","LU0708995583.HKD","BK1610","LU0140636845.USD","SG9999002562.SGD","LU0051755006.USD","LU0348735423.USD","LU0043850808.USD","LU0456827905.SGD","LU2039709279.SGD","LU0307460666.USD","LU0856984785.SGD","LU0181495838.USD"],"gpt_icon":1}],"pageSize":16,"totalPage":13,"pageCount":12,"totalSize":200}]}}